Cargando…
The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/ https://www.ncbi.nlm.nih.gov/pubmed/27786238 http://dx.doi.org/10.1038/srep35770 |
_version_ | 1782462917604540416 |
---|---|
author | Ye, Sa Li, Jiuke Hao, Ke Yan, Jianping Zhou, Hongbin |
author_facet | Ye, Sa Li, Jiuke Hao, Ke Yan, Jianping Zhou, Hongbin |
author_sort | Ye, Sa |
collection | PubMed |
description | c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of these drugs from 9 studies including 1611 patients in target drug groups and 1605 patients in control groups. As a result, patients in target drugs group had longer progression free survival (PFS) (HR 0.80, 95% CI 0.66–0.99, p = 0.04) but not overall survival (OS) than those in control group, especially in Asian (HR 0.57, 95% CI 0.42–0.76, p < 0.001), Non-squamous (HR 0.79, 95% CI 0.64–0.97, p = 0.03), Phase III (HR 0.66, 95% CI 0.50–0.86, p = 0.002), previous treated (HR 0.77, 95% CI 0.63–0.95, p = 0.01) and small molecular compounds subgroups (HR 0.62, 95% CI 0.50–0.78, p < 0.001). In addition, target drugs did not affect the objective response rate (ORR) but improved disease control rate (DCR) (RR 1.22, 95% CI 1.02–1.46, p = 0.03) of NSCLC patients. Our study first indicated that targeting c-MET therapies improved PFS and DCR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma. |
format | Online Article Text |
id | pubmed-5081544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50815442016-10-31 The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis Ye, Sa Li, Jiuke Hao, Ke Yan, Jianping Zhou, Hongbin Sci Rep Article c-MET inhibitors are considered as a kind of novel drugs in non-small cell lung cancer (NSCLC) treatment. However, the results of different clinical studies involving c-MET inhibitors were not consistent. In this report, we performed Meta-analysis to investigate the beneficial and harmful effects of these drugs from 9 studies including 1611 patients in target drug groups and 1605 patients in control groups. As a result, patients in target drugs group had longer progression free survival (PFS) (HR 0.80, 95% CI 0.66–0.99, p = 0.04) but not overall survival (OS) than those in control group, especially in Asian (HR 0.57, 95% CI 0.42–0.76, p < 0.001), Non-squamous (HR 0.79, 95% CI 0.64–0.97, p = 0.03), Phase III (HR 0.66, 95% CI 0.50–0.86, p = 0.002), previous treated (HR 0.77, 95% CI 0.63–0.95, p = 0.01) and small molecular compounds subgroups (HR 0.62, 95% CI 0.50–0.78, p < 0.001). In addition, target drugs did not affect the objective response rate (ORR) but improved disease control rate (DCR) (RR 1.22, 95% CI 1.02–1.46, p = 0.03) of NSCLC patients. Our study first indicated that targeting c-MET therapies improved PFS and DCR in advanced or metastatic NSCLC patients, especially in previous treated Asian patients with adenocarcinoma. Nature Publishing Group 2016-10-27 /pmc/articles/PMC5081544/ /pubmed/27786238 http://dx.doi.org/10.1038/srep35770 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Ye, Sa Li, Jiuke Hao, Ke Yan, Jianping Zhou, Hongbin The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title | The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title_full | The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title_fullStr | The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title_full_unstemmed | The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title_short | The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis |
title_sort | efficacy and risk profile of c-met inhibitors in non-small cell lung cancer: a meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081544/ https://www.ncbi.nlm.nih.gov/pubmed/27786238 http://dx.doi.org/10.1038/srep35770 |
work_keys_str_mv | AT yesa theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT lijiuke theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT haoke theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT yanjianping theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT zhouhongbin theefficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT yesa efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT lijiuke efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT haoke efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT yanjianping efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis AT zhouhongbin efficacyandriskprofileofcmetinhibitorsinnonsmallcelllungcancerametaanalysis |